Blog

The father of the deaf and his battle with Diabetes || Part-03

🔖 Pathogenesis of Diabetes:

Diabetes āĻāĻ•āϟāĻž multifactorial diseaseāĨ¤ āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻ…āύ⧇āĻ• āϰāĻ•āĻŽā§‡āϰ factor āĻāϰ interplay āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻāχ disease āĻšā§Ÿā§‡ āĻĨāĻžāϕ⧇āĨ¤ āĻāχ factor āϗ⧁āϞ⧋ āĻŽā§‚āϞāϤ ⧍āϟāĻž category āϤ⧇ āĻĒā§œā§‡ – genetic factors āφāϰ environmental factorsāĨ¤

⭕ Pathogenesis of Type-1 diabetes:

āĻĒā§āϰāĻĨāĻŽā§‡āχ āφāϏāĻŋ type 1 diabetes āĻāϰ pathogenesis āĻāĨ¤ āĻāϟāĻŋ āĻŽā§‚āϞāϤ āĻāĻ•āϟāĻž autoimmune disease, āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻāĻ–āĻžāύ⧇ body āĻāϰ āύāĻŋāĻœā§‡āϰ immune system āύāĻŋāĻœā§‡āϰ cells & tissues (āĻāĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ pancreas āĻāϰ β cell) āϕ⧇ attack āĻ•āϰ⧇āĨ¤ Ultimate effect āĻšāĻšā§āϛ⧇ β cell āĻāϰ destructionāĨ¤

Type 1 diabetes āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ genetic factor āϗ⧁āϞ⧋āχ āĻĒā§āϰāϧāĻžāύ āĻ­ā§‚āĻŽāĻŋāĻ•āĻž āϰāĻžāϖ⧇āĨ¤ āĻĒā§āϰāĻžā§Ÿ ā§Šā§ĻāϟāĻŋāϰ āĻŦ⧇āĻļāĻŋ gene āĻāϰ mutation āĻāϰ āϏāĻžāĻĨ⧇ type 1 diabetes āĻāϰ āϏāĻŽā§āĻĒāĻ°ā§āĻ• āĻĒāĻžāĻ“ā§ŸāĻž āĻ—āĻŋā§Ÿā§‡āϛ⧇āĨ¤ āĻāϗ⧁āϞ⧋āϰ āĻŽāĻ§ā§āϝ⧇ MHC āĻŦāĻž HLA gene cluster āĻāϰ mutation āϏāĻŦāĻšā§‡ā§Ÿā§‡ common, āĻĒā§āϰāĻžā§Ÿ ā§Ģā§Ļ%āĨ¤ Non-MHC gene āϗ⧁āϞ⧋āϰ āĻŽāĻ§ā§āϝ⧇ āĻ°ā§Ÿā§‡āϛ⧇ insulin gene, CTLA4 gene, PTPN22 gene, Autoimmune Regulator (AIRE) gene āχāĻ¤ā§āϝāĻžāĻĻāĻŋāĨ¤

Fig : Pathogenesis of Type-1 Diabetes Mellitus.

āĻŽā§‚āϞāϤ genetic factor āϗ⧁āϞ⧋āχ āĻĻāĻžā§Ÿā§€ āĻšāϞ⧇āĻ“ āĻ•āĻŋāϛ⧁ environmental factor āĻāϰ āĻ­ā§‚āĻŽāĻŋāĻ•āĻžāĻ“ āĻ°ā§Ÿā§‡āϛ⧇ type 1 diabetes āĻāϰ pathogenesis āĻāĨ¤ āϧāĻžāϰāĻŖāĻž āĻ•āϰāĻž āĻšā§Ÿ āϝ⧇, āĻ•āĻŋāϛ⧁ viral infection āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ autoimmune process āϟāĻž trigger āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āϝāĻžāϰ āĻŽā§‚āϞ āĻ•āĻžāϰāĻŖ āĻšāĻŋāϏ⧇āĻŦ⧇ āϧāϰāĻž āĻšā§Ÿā§‡āϛ⧇ molecular mimicryāĨ¤ āĻ…āĻ°ā§āĻĨāĻžā§Ž, viral antigen āϗ⧁āϞ⧋āϰ āϏāĻžāĻĨ⧇ host antigen āĻāϰ structure āĻ āĻŽāĻŋāϞ āĻĨāĻžāĻ•āĻžā§Ÿ cross-react āĻ•āϰ⧇āĨ¤

Type 1 diabetes āĻāϰ āĻŽā§‚āϞ abnormality āχ āĻšāĻšā§āϛ⧇ failure of self-toleranceāĨ¤ āĻāχ failure āĻ…āύ⧇āĻ•āĻ­āĻžāĻŦ⧇āχ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ – āϝ⧇āĻŽāύ self-reactive T cell āĻāϰ clonal deletion āϝāĻĻāĻŋ defective āĻšā§Ÿ āĻ…āĻĨāĻŦāĻž regulatory T cell āĻāϰ function āϝāĻĻāĻŋ defective āĻšā§ŸāĨ¤ Ultimately, āĻāχ self-reactive T cell āϗ⧁āϞ⧋āχ β cell āĻāϰ destruction āĻ•āϰ⧇āĨ¤ Helper T cell āϗ⧁āϞ⧋ āύāĻžāύāĻžāϰāĻ•āĻŽ cytokine āϝ⧇āĻŽāύ TNF, IFN-Îŗ āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ damage āĻ•āϰ⧇, āĻ…āĻ¨ā§āϝāĻĻāĻŋāϕ⧇ cytotoxic T cell āϗ⧁āϞ⧋ directly damage āĻ•āϰ⧇āĨ¤

āĻāĻ›āĻžā§œāĻžāĻ“ islet autoantigen āĻāϰ against āĻ autoantibody āĻ“ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ autoantibody āϗ⧁āϞ⧋ cell damage āĻ•āϰ⧇ āĻ•āĻŋāύāĻž āĻŦāĻž āĻ•āϰāϞ⧇āĻ“ āĻ•āĻŋāĻ­āĻžāĻŦ⧇ āĻ•āϰ⧇ āϤāĻž āĻāĻ–āύ⧋ āϏāĻ āĻŋāĻ•āĻ­āĻžāĻŦ⧇ āϜāĻžāύāĻž āϝāĻžā§ŸāύāĻŋ, āϤāĻžāχ autoantibody āϗ⧁āϞ⧋ predictive marker āĻšāĻŋāϏ⧇āĻŦ⧇ use āĻ•āϰāĻž āĻšā§ŸāĨ¤

āĻāχāϝ⧇ islet autoantigen āĻāϰ āĻ•āĻĨāĻž āĻŦāϞāϞāĻžāĻŽ āϝāĻžāϕ⧇ target āĻ•āϰ⧇ T cell āϗ⧁āϞ⧋ activate āĻšā§Ÿ āφāĻŦāĻžāϰ antibody āĻ“ āϤ⧈āϰāĻŋ āĻšāĻšā§āϛ⧇, āĻāχ islet autoantigen āĻāϰ āĻŽāĻ§ā§āϝ⧇ āĻ°ā§Ÿā§‡āϛ⧇

  • insulin (insulin āĻĒā§āϰ⧋āϟāĻŋāύ āĻāϰ against āĻāχ autoimmunity āĻšāĻšā§āϛ⧇),
  • β cell GAD (GAD āĻšāϞ⧋ āĻāĻ•āϟāĻž āĻāύāϜāĻžāχāĻŽ, glutamic acid decarboxylase) āĻāĻŦāĻ‚
  • islet cell autoantigen 512

āϤāĻžāĻšāϞ⧇ āĻĒ⧁āϰ⧋ process āϟāĻž āĻĻāĻžāρ⧜āĻžāĻšā§āϛ⧇ āĻ…āύ⧇āĻ•āϟāĻž āĻāϰāĻ•āĻŽ –

genetic & environmental factors ➤ failure of self-tolerance ➤ activation of self-reactive T cells against islet antigens ➤ damage of β cells ➤ insulin deficiency ➤ Type 1 DM

Type 2 Diabetes, āĻāĻ–āĻžāύ⧇āĻ“ genetic factor āφāϰ environmental factor āϝāĻĻāĻŋāĻ“ āĻāĻ–āĻžāύ⧇ environmental factor āϗ⧁āϞ⧋āϰ āĻĒā§āϰāĻ­āĻžāĻŦ āĻŦ⧇āĻļāĻŋāĨ¤ āφāϰ āĻāϟāĻž Type 1 āĻāϰ āĻŽāϤ āϕ⧋āύ⧋ autoimmune disease āύāĻžāĨ¤

Genetic factor āϝ⧇āϗ⧁āϞ⧋ āĻ°ā§Ÿā§‡āϛ⧇ āϏ⧇āϗ⧁āϞ⧋ āϏāĻŦāχ insulin secretion āĻāϰ āϏāĻžāĻĨ⧇ related geneāĨ¤ āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻāĻ–āĻžāύ⧇ genetic defect āϗ⧁āϞāĻžāϰ āĻ•āĻžāϰāϪ⧇ insulin āĻāϰ secretion āĻ abnormality āĻšāĻŦ⧇āĨ¤

Environmental factor āϗ⧁āϞ⧋āϰ āĻŽāĻ§ā§āϝ⧇ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻšāĻšā§āϛ⧇ obesityāĨ¤ āĻāϰ āĻĒāϰ⧇āχ āĻ°ā§Ÿā§‡āϛ⧇ sedentary life styleāĨ¤

⭕ Pathogenesis of type-2 diabetes:

āĻāĻŦāĻžāϰ āφāϏāĻŋ āĻ•āĻŋāĻ­āĻžāĻŦ⧇ āφāϏāϞ⧇ type 2 diabetes āϟāĻž āĻšāĻšā§āϛ⧇āĨ¤ āĻāĻ–āĻžāύ⧇ āĻŽā§‚āϞāϤ ⧍ āϰāĻ•āĻŽ defect āĻĻ⧇āĻ–āĻž āϝāĻžā§Ÿ – insulin resistance āĻāĻŦāĻ‚ β cell dysfunctionāĨ¤

Fig : Pathogenesis of Type-2 Diabetes Mellitus.

āĻĒā§āϰāĻĨāĻŽāĻĻāĻŋāϕ⧇ insulin resistance āĻĻāĻŋā§Ÿā§‡ āĻļ⧁āϰ⧁ āĻšā§Ÿ, āϤāĻ–āύ āĻāϕ⧇ compensate āĻ•āϰāϤ⧇ āĻ—āĻŋā§Ÿā§‡ β cell āĻāϰ function āĻŦā§‡ā§œā§‡ āϝāĻžā§Ÿ āĻāĻŦāĻ‚ hyperinsulinemia āĻĻ⧇āĻ–āĻž āϝāĻžā§ŸāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏāĻŽā§Ÿā§‡āϰ āϏāĻžāĻĨ⧇ āϏāĻžāĻĨ⧇ āĻāĻ• āϏāĻŽā§Ÿ β cell āϗ⧁āϞ⧋ āφāϰ adapt āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āύāĻž āφāϰ āϤāĻ–āύ āĻĨ⧇āϕ⧇āχ āĻļ⧁āϰ⧁ āĻšā§Ÿ β cell dysfunctionāĨ¤

◾ Insulin Resistance:

āϝāĻ–āύ insulin āĻāϰ target tissue āϗ⧁āϞ⧋ āĻ…āĻ°ā§āĻĨāĻžā§Ž liver, skeletal muscle, adipose tissue āĻāϰ āϏāĻ āĻŋāĻ•āĻ­āĻžāĻŦ⧇ insulin āĻāϰ āĻĒā§āϰāϤāĻŋ respond āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇ āύāĻž, āϤāĻ–āύ āϤāĻžāϕ⧇ insulin resistance āĻŦāϞ⧇āĨ¤

Insulin resistance āĻāϰ āĻ…āĻ¨ā§āϝāϤāĻŽ āĻĒā§āϰāϧāĻžāύ āĻ•āĻžāϰāĻŖ āĻšāĻšā§āϛ⧇ obesity.

★ Obesity āĻ•āĻŋāĻ¨ā§āϤ⧁ distribution āĻ…āύ⧁āϏāĻžāϰ⧇ ⧍ āϰāĻ•āĻŽ, central āφāϰ peripheralāĨ¤ āĻāϰ āĻŽāĻ§ā§āϝ⧇ central fat āϗ⧁āϞ⧋āϤ⧇ lipolysis āĻŦ⧇āĻļāĻŋ āĻšā§ŸāĨ¤ āĻĢāϞ⧇ āĻŦ⧇āĻļāĻŋ āĻŦ⧇āĻļāĻŋ fatty acid āϤ⧈āϰāĻŋ āĻšā§Ÿ that is excess free fatty acids (FFAs) in bloodāĨ¤ āĻāχ excess FFAs āĻ—āĻŋā§Ÿā§‡ cell āĻāϰ āĻ­āĻŋāϤāϰ⧇āϰ oxidation pathway āϗ⧁āϞ⧋āϕ⧇ overwhelm āĻ•āϰ⧇ āĻĢ⧇āϞ⧇āĨ¤ āĻĢāϞ⧇ āĻĻ⧇āĻ–āĻž āϝāĻžā§Ÿ pathway āϗ⧁āϞ⧋ āĻ āĻŋāĻ•āĻŽāϤ⧋ āϚāϞāϤ⧇ āĻĒāĻžāϰ⧇ āύāĻž āĻāĻŦāĻ‚ āĻāϏāĻŦ pathway āĻāϰ āĻ•āĻŋāϛ⧁ intermediate product āϕ⧋āώ āĻāϰ āĻ­āĻŋāϤāϰ⧇ āϜāĻŽāϤ⧇ āĻĨāĻžāϕ⧇āĨ¤ āĻāϰāĻ•āĻŽ āĻāĻ•āϟāĻŋ intermediate product āĻšāĻšā§āϛ⧇ diacylglycerol (DAG)āĨ¤ āĻāχ DAG āĻ—āĻŋā§Ÿā§‡ insulin āĻāϰ intracellular āϝ⧇ signalling āĻšā§Ÿ āϏ⧇āϟāĻžāϰ āϏāĻžāĻĨ⧇ interfere āĻ•āϰ⧇āĨ¤ Ultimately, insulin āĻāϰ desired effect āϟāĻž āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻž, result is insulin resistanc.

★ āĻāχ excess FFA āϗ⧁āϞ⧋ āφāĻŦāĻžāϰ cell āĻāϰ āĻ­āĻŋāϤāϰ⧇ oxidation āĻāϰ āϜāĻ¨ā§āϝ glucose āĻāϰ āϏāĻžāĻĨ⧇ compete āĻ•āϰ⧇āĨ¤ āϝāϤ āĻŦ⧇āĻļāĻŋ āĻŦ⧇āĻļāĻŋ fatty acid āĻāϰ oxidation āĻšā§Ÿ, glucose āĻāϰ oxidation āϤāϤ āĻ•āĻŽāϤ⧇ āĻĨāĻžāϕ⧇, this leads to accumulation of glucoseāĨ¤ Cell āĻāϰ āĻ­āĻŋāϤāϰ⧇ glucose āϜāĻŽā§‡ āϗ⧇āϞ⧇ āĻŦāĻžāχāϰ⧇ āĻĨ⧇āϕ⧇ āĻ…āĻ°ā§āĻĨāĻžā§Ž blood āĻĨ⧇āϕ⧇ glucose entry āĻ•āĻŽā§‡ āϝāĻžāĻŦ⧇, āϤāĻ–āύ blood āĻ glucose level āĻŦāĻžā§œāϤ⧇ āĻĨāĻžāĻ•āĻŦ⧇, that is hyperglycemiaāĨ¤

★ āĻāĻ›āĻžā§œāĻžāĻ“ obesity āϤ⧇ adiponectin level āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āĻ•āĻžāϰāϪ⧇āĻ“ blood glucose level āĻŦāĻžā§œā§‡āĨ¤ āĻāχ adiponectin āĻšāϞ⧋ āĻāĻ• āϧāϰāϪ⧇āϰ adipokine (adipose tissue āĻĨ⧇āϕ⧇ release āĻšāĻ“ā§ŸāĻž āĻ•āĻŋāϛ⧁ āĻĒā§āϰ⧋āϟāĻŋāύ āϕ⧇ adipokine āĻŦāϞ⧇)āĨ¤ Adipokine āĻŽā§‚āϞāϤ blood glucose āĻ•āĻŽāĻžā§Ÿ, obesity āϤ⧇ adipokine level āĻ•āĻŽā§‡ āϝāĻžā§Ÿ āĻŦāϞ⧇ blood glucose level āĻŦā§‡ā§œā§‡ āϝāĻžā§ŸāĨ¤

Fig : Development of Type-2 Diabetes Mellitus.

◾ β cell dysfunction:
āĻ…āύ⧇āĻ•āĻĻāĻŋāύ āϧāϰ⧇ insulin resistance āϚāϞāϤ⧇ āĻĨāĻžāĻ•āϞ⧇ āĻāĻ• āϏāĻŽā§Ÿ β cell āϗ⧁āϞ⧋ āφāϰ adapt āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇ āύāĻž āĻāĻŦāĻ‚ āĻļ⧁āϰ⧁ āĻšā§Ÿ β cell dysfunctionāĨ¤ excess FFAs āĻāĻŦāĻ‚ chronic hyperglycemia āĻāϰ āĻ•āĻžāϰāϪ⧇āχ āĻŽā§‚āϞāϤ β cell dysfunction āĻšāϤ⧇ āĻĨāĻžāϕ⧇āĨ¤

🔖 Sign-symptoms of Diabetes:

āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϏāĻžāϧāĻžāϰāĻŖ āωāĻĒāϏāĻ°ā§āĻ—āϗ⧁āϞ⧋āϰ āĻŽāĻ§ā§āϝ⧇ āϰāϝāĻŧ⧇āϛ⧇:

â™Ļ āϖ⧁āĻŦ āϤ⧃āĻˇā§āĻŖāĻž āĻĒāĻžāĻ“āϝāĻŧāĻž
â™Ļ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāϕ⧇āϰ āϚāĻžāχāϤ⧇āĻ“ āϘāύ āϘāύ āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ āĻšāĻ“āϝāĻŧāĻžāĨ¤ āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ āϰāĻžāϤ⧇āϰ āĻŦ⧇āϞāĻžāϝāĻŧāĨ¤
â™Ļ āĻ•ā§āϞāĻžāĻ¨ā§āϤ āĻŦā§‹āϧ āĻ•āϰāĻž
â™Ļ āϕ⧋āύ āĻ•āĻžāϰāĻŖ āĻ›āĻžāĻĄāĻŧāĻžāχ āĻ“āϜāύ āĻ•āĻŽā§‡ āϝāĻžāĻ“āϝāĻŧāĻž
â™Ļ āĻĒā§āϰāĻĻāĻžāĻšāϜāύāĻŋāϤ āϰ⧋āϗ⧇ āĻŦāĻžāϰāĻŦāĻžāϰ āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻšāĻ“āϝāĻŧāĻž
â™Ļ āĻĻ⧃āĻˇā§āϟāĻŋ āĻāĻžāĻĒāϏāĻž āĻšāϝāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻž
â™Ļ āĻļāϰ⧀āϰ⧇āϰ āϕ⧋āĻĨāĻžāĻ“ āϕ⧇āĻŸā§‡ āϗ⧇āϞ⧇ āϏ⧇āϟāĻž āĻļ⧁āĻ•āĻžāϤ⧇ āĻĻ⧇āϰāĻŋ āĻšāĻ“ā§ŸāĻž

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•āϰāĻž āĻŦāϞāϛ⧇āύ, type-1 diabetes sign-symptoms āĻļ⧈āĻļāĻŦ āĻĨ⧇āϕ⧇āχ āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϤ⧇ āĻĒāĻžāϰ⧇ āĻāĻŦāĻ‚ āĻŦāϝāĻŧāϏ āĻŦāĻžāĻĄāĻŧāĻžāϰ āϏāĻžāĻĨ⧇ āϏ⧇āϟāĻž āφāϰ⧋ āϜāϟāĻŋāϞ āĻšāϝāĻŧ⧇ āωāĻ āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Fig : Sign-symptoms of Type-1 Diabetes Mellitus.

āĻŦāϝāĻŧāϏ ā§Ēā§Ļ āĻŦāĻ›āϰ⧇āϰ āĻŦ⧇āĻļāĻŋ āĻšāĻ“āϝāĻŧāĻžāϰ āĻĒāϰ āĻĨ⧇āϕ⧇ type-2 diabetes āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦ⧇āĻĄāĻŧ⧇ āϝāĻžāϝāĻŧāĨ¤ āϤāĻŦ⧇ āĻĻāĻ•ā§āώāĻŋāĻŖ āĻāĻļāĻŋāϝāĻŧāĻžāϰ āϞ⧋āĻ•āϜāύ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻāχ āĻā§āρāĻ•āĻŋ āϤ⧈āϰāĻŋ āĻšāϝāĻŧ āϤāĻžāĻĻ⧇āϰ ⧍ā§Ģ āĻŦāĻ›āϰ āĻŦāϝāĻŧāϏ āĻšāĻ“āϝāĻŧāĻžāϰ āĻĒāϰ āĻĨ⧇āϕ⧇āχāĨ¤

āϝāĻžāĻĻ⧇āϰ āĻĒāĻŋāϤāĻžāĻŽāĻžāϤāĻž, āĻ­āĻžāχ āĻŦā§‹āύ⧇āϰ diabetes āφāϛ⧇, āĻ…āĻĨāĻŦāĻž āϝāĻžāĻĻ⧇āϰ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ“āϜāύ, āĻĻāĻ•ā§āώāĻŋāĻŖ āĻāĻļāĻŋāϝāĻŧāĻžāϰ āϕ⧋āύ āĻĻ⧇āĻļ⧇āϰ āĻŽāĻžāύ⧁āώ, āφāĻĢā§āϰ⧋-āĻ•ā§āϝāĻžāϰāĻŋāĻŦāĻŋāϝāĻŧāĻžāύ āĻ…āĻĨāĻŦāĻž āĻ•ā§ƒāĻˇā§āĻŖāĻžāĻ™ā§āĻ— āφāĻĢā§āϰāĻŋāĻ•āĻžāύ āϤāĻžāĻĻ⧇āϰāĻ“ āĻāχ āĻā§āρāĻ•āĻŋ āĻŦ⧇āĻļāĻŋ āĻĨāĻžāϕ⧇āĨ¤

🔖 Complications of Diabetes:

Fig : Complications of Diabetes Mellitus.

Diabetes āĻāϰ complications āϗ⧁āϞ⧋āϕ⧇ āĻŽā§‚āϞāϤ ā§Š āĻ­āĻžāϗ⧇ āĻ­āĻžāĻ— āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

⭕ Macro vascular complications ( āϝ⧇āĻ–āĻžāύ⧇ āĻŦ⧜ āϰāĻ•ā§āϤāύāĻžāϞ⧀ āĻ•ā§āώāϤāĻŋāĻ—ā§āϰāĻ¸ā§āϤ āĻšā§Ÿ):

â™Ļ Coronary artery disease (CAD)
e.g: ischaemic heart attack

â™Ļ Cerebro vascular disease (CVD)
e.g: stroke, transient ischaemic attack

â™Ļ Peripheral vascular disease (PVD)
e.g: feet gangrene

⭕ Micro vascular complications ( āϝ⧇āĻ–āĻžāύ⧇ āϛ⧋āϟ āϰāĻ•ā§āϤāύāĻžāϞ⧀ āĻ•ā§āώāϤāĻŋāĻ—ā§āϰāĻ¸ā§āϤ āĻšā§Ÿ)

â™Ļ Diabetic neuropathy
â™Ļ Diabetic nephropathy
â™Ļ Diabegic retinopathy

⭕ Diabetic cataract

āĻāĻ›āĻžā§œāĻž āĻāχ āĻŽāĻšāĻžāĻŽāĻžāϰ⧀ āĻāϰ āϏāĻŽā§Ÿā§‡ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āĻŦ⧇āĻļāĻŋ āĻā§āĻ•āĻŋāϤ⧇ diabetic patientāĨ¤āφāĻŽāĻžāĻĻ⧇āϰ āĻĻ⧇āĻļ⧇ diabetes āϰ⧋āĻ—ā§€āϰ āϏāĻ‚āĻ–ā§āϝāĻž āĻ…āύ⧇āĻ•āĨ¤ āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ āĻŦ⧟āĻ¸ā§āĻ• āĻŦā§āϝāĻ•ā§āϤāĻŋāĻĻ⧇āϰ āĻ…āύ⧇āϕ⧇āϰāχ diabetes āφāϛ⧇āĨ¤ āϤāĻžāϰ āĻ“āĻĒāϰ āφāĻŽāĻžāĻĻ⧇āϰ diabetes āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻāĻ•āϟāĻŋ āĻŦāĻŋāϰāĻžāϟ āĻ…āĻ‚āĻļ⧇āϰ blood glucose āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇āϰ āĻŦāĻžāχāϰ⧇āĨ¤ diabetes āĻāϰ āĻ•āĻžāϰāϪ⧇ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āϰ⧋āĻ— āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĻ•ā§āώāĻŽāϤāĻž āĻ•āĻŽā§‡ āϝāĻžā§ŸāĨ¤ āĻāĻ›āĻžā§œāĻžāĻ“ pandemic situation āĻāϰ āϜāĻ¨ā§āϝ āĻ…āύ⧇āϕ⧇ patient exercise āĻ•āϰāϤ⧇ āĻĒāĻžāϰāϛ⧇āύāĻž āϝ⧇āϟāĻžāϰ āĻ•āĻžāϰāϪ⧇ uncontrolled diabetes āĻšāĻšā§āϛ⧇āĨ¤ āϝ⧇āϕ⧋āύ⧋ āĻœā§€āĻŦāĻžāϪ⧁āϰ āϏāĻ™ā§āϗ⧇ āϞ⧜āĻžāχ āĻ•āϰāĻžāϰ āϏāĻ•ā§āώāĻŽāϤāĻž āĻšā§āϰāĻžāϏ āĻĒāĻžā§ŸāĨ¤ āφāĻŦāĻžāϰ diabetes āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻāĻ•āχ āϏāĻ™ā§āϗ⧇ kidney disease, heart disease āχāĻ¤ā§āϝāĻžāĻĻāĻŋ āĻĨāĻžāϕ⧇āĨ¤ diabetes āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻŦ⧜ āϧāϰāύ⧇āϰ āĻā§āρāĻ•āĻŋ āφāϛ⧇ corona virus āĻ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŋāϤ āĻšāĻ“ā§ŸāĻžāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇āĨ¤

Reference:

â™Ļ Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, United States: Saunders; 2015. Chapter 24: The Endocrine System; p1109-1112.

â™Ļ Pearson ER, McCrimmon RJ. Diabetes Mellitus. In: Ralston SH, Penman ID, Strachan MWJ, & Hobson R. (Eds.). Davidson’s Principles and Practice of Medicine. 23rd ed. London, England: Elsevier Health Sciences; 2018. p725-727.

Platform Academic Divison/

āφāϏāĻžāĻĻ⧁āϞ āφāϞ āĻ—āĻžāϞāĻŋāĻŦ
āĻ¸ā§āϝāĻžāϰ āϏāϞāĻŋāĻŽā§āĻ˛ā§āϞāĻžāĻš āĻŽā§‡āĻĄāĻŋāϕ⧇āϞ āĻ•āϞ⧇āϜ
āϏ⧇āĻļāύāσ⧍ā§Ļā§§ā§Ŧ-⧍ā§Ļā§§ā§­

āύ⧇āĻšāĻž āĻ–āĻžāύ
āχāωāύāĻŋāĻ­āĻžāĻ°ā§āϏ⧇āϞ āĻŽā§‡āĻĄāĻŋāϕ⧇āϞ āĻ•āϞ⧇āϜ
āϏ⧇āĻļāύāσ⧍ā§Ļā§§ā§­-⧍ā§Ļā§§ā§Ž

One thought on “The father of the deaf and his battle with Diabetes || Part-03

  1. Pingback: The father of the deaf and his battle with Diabetes || Part-04 – Platform | CME

Leave a Reply